Venclexta, developed by AbbVie and Roche, has received FDA approval. The drug is designed to treat acute myeloid leukemia at an early stage in adults aged 75 years and older, as well as in patients with concomitant diseases that do not use intensive chemotherapy. In the U.S. companies commercialize it jointly, and outside the country it is commercialized by AbbVie under the Venclyxto brand name.